Patents Represented by Attorney, Agent or Law Firm Felfe & Lynch
  • Patent number: 6310185
    Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: October 30, 2001
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Thomas P. Wallace, Kathryn Lesley Armour, Francis Joseph Carr, Lloyd J. Old, Elisabeth Stockert, Sydney Welt, Kunio Kitamura, Pilar Garin-Chesa
  • Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Patent number: 6253142
    Abstract: The coefficient of friction &mgr;s between the wheels of the vehicle and the road surface is identified as a function of the slip, and the maximum drive torque MAmax which can be transmitted is determined as a function of this slip-dependent coefficient of friction &lgr;. &lgr; is corrected when there is an increased slip requirement &lgr;erf as a result of the speed of the vehicle and/or the tire mixture used.
    Type: Grant
    Filed: August 25, 1995
    Date of Patent: June 26, 2001
    Assignee: Robert Bosch GmbH
    Inventors: Thomas Sauter, Peter Daubner
  • Patent number: 6235525
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: May 22, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit van den Eynde, Pierre van der Bruggen, Thierry Boon-Falleur
  • Patent number: 6150437
    Abstract: Flow improving agents for binder suspensions containing cement are described, which consist of:a) Graft polymers which have been prepared by radical grafting of a polyalkylene oxide of the general formula (I) with an ethylenically unsaturated mono- or dicarboxylic acid or the anhydride thereof, and then by derivatizing with a primary or secondary amine and/or alcohol, and also ofb) Casein.These flow improving agents have the advantage that the ability to flow is considerably improved in comparison, for example, with casein alone, and the improved ability to flow is preserved over a longer period of time.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 21, 2000
    Assignee: SKW Trostberg Aktiengesellschaft
    Inventors: Konrad Wutz, Alfred Kern, Josef Weichmann
  • Patent number: 6140464
    Abstract: The invention described methods for identifying a molecule of interest, as well as nucleic acid molecules which encode it, and binding partners for it. A cDNA library from a cell expressing the target is prepared, and expressed in host cells. Lysates of the host cells are screened with a sample, treated to remove interfering binding partners. The treatment involves contact of the sample to lysates of untransfected host cells, and host cells transfected or transformed with the same vector used to make the cDNA library. Also a part of the invention are antigens and cDNA identified using the methodology.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: October 31, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Michael Pfreundschuh, Hans-Georg Rammensee
  • Patent number: 6057115
    Abstract: The invention relates to the production of ganglioside specific antibodies. These antibodies are produced following immunization with lipopolysaccharide antigen of Campylobacter jejuni. The antibodies bind to monosialogangliosides, including GM2 and GM1.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: May 2, 2000
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Gerd Ritter, Lloyd J. Old
  • Patent number: 6056451
    Abstract: A photographic film processing apparatus for processing long developed film (10b) formed by joining photographic films with a splicing material (13). The apparatus includes a first transport device (40a) for transporting the long developed film. A region of the splicing material in the long developed film is detected in order to cut the long film. A main cutter (60) cuts the long developed film transported by the first transport device, in the region of the splicing material into short films (10a) prior to an exposing process. A second transport device (40b) is provided for transporting the short films to exposure processing units (20, 30). Further, an auxiliary cutter (70) is provided for cutting lateral portions of the region of the splicing material in the long developed film. The region of the splicing material is cut such that a width of an upstream short film is contained within a width at a forward end of a downstream short film.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: May 2, 2000
    Assignee: Noritsu Koko Co., Ltd.
    Inventors: Kohji Seki, Yoshiyuki Yamaji
  • Patent number: 6025191
    Abstract: The invention involves the isolation of a nucleic acid molecule which encodes a melanoma associated antigen. Cell lines and expression vectors which include this and related sequences, as well as uses of these molecules, are described.
    Type: Grant
    Filed: January 3, 1996
    Date of Patent: February 15, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventor: Michael Pfreundschuh
  • Patent number: 5965424
    Abstract: The present invention concerns a process for the isolation of recombinant IgA protease from inclusion bodies. In addition a recombinant DNA is claimed which codes for an IgA protease whose C-terminal helper sequence and preferably also its N-terminal signal sequence is no longer active.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: October 12, 1999
    Assignee: Boehringer Mannheim GmbH
    Inventors: Dorothea Ambrosius, Carola Dony, Rainer Rudolph
  • Patent number: 5932694
    Abstract: The invention involves the identification of an isolated nucleic acid molecule which encodes a tumor rejection antigen. Various uses of this nucleic acid molecule and the protein it encodes are discussed.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: August 3, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Susanna Mandruzzato, Thierry Boon-Falleur
  • Patent number: 5925729
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: July 20, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Patent number: 5918952
    Abstract: A processing circuit has a computing cycle divided into several subcycles of uniform duration. The time base values of the last three nulls of a square wave signal produced from the sinusoidal signal of a wheel speed sensor are stored in a register with three places. At the beginning of a subcycle the difference D of the latest and of the oldest time base values stored in the register is formed and in some cases after limiting is converted to a value 1/D and stored, while the previously stored oldest value is erased. At the start of a new computing cycle the stored value 1/D is further processed as the new wheel speed.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: July 6, 1999
    Assignee: Robert Bosch GmbH
    Inventors: Carlos Atoche-Juarez, Peter Dominke, Werner Weber, Edgar Bernardi
  • Patent number: 5879063
    Abstract: A processing circuit has a computing cycle divided into several subcycles of uniform duration. The time base values of the last three nulls of a square wave signal produced from the sinusoidal signal of a wheel speed sensor are stored in a register with three places. At the beginning of a subcycle the difference D of the latest and of the oldest time base values stored in the register is formed and in some cases after limiting is converted to a value 1/D and stored, while the previously stored oldest value is erased. At the start of a new computing cycle the stored value 1/D is further processed as the new wheel speed.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: March 9, 1999
    Assignee: Robert Bosch GmbH
    Inventors: Carlos Atoche-Juarez, Peter Dominke, Werner Weber, Edgar Bernardi
  • Patent number: 5877017
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: March 2, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Patent number: 5867460
    Abstract: In an apparatus for the laser beam exposure of a substrate disc (5), linked block tables (19, 29) are provided, which have each a piezotranslator (24, 31). This makes it possible to perform a fine correction of the movements very rapidly and very precisely.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: February 2, 1999
    Assignee: Balzers und Leybold Deutschland Holding AG
    Inventors: Bernd Hensel, Friedrich Hofmann, Hermann Koop, Paul Kaiser, Eberhard Feick, Franz Richter
  • Patent number: 5864015
    Abstract: The invention describes identification and isolation of molecules associated specifically with Hodgkin's Disease. Uses of the molecules are described as well.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: January 26, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventor: Michael Pfreundschuh
  • Patent number: 5859314
    Abstract: A non-human animal carrying a disruption of a gene encoding a lyn protein tyrosine kinase provides a convenient system for the study of diseases associated with or caused by lyn deficiency, and for the testing of therapeutic agents for the treatment or prevention of diseases which include autoimmune diseases, allergy, asthma and malignant disease.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: January 12, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Margaret L. Hibbs, Ashley R. Dunn, Dianne Graill, George Hodgson, David M. Tarlington, Jane Armes
  • Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Patent number: 5853668
    Abstract: A first reactant is immobilized i.e. in a porous matrix (50), adjacent a sample electrode (46) within a reaction chamber. Energizing of the electrode (46) electrophoretically attracts a mobile second reactant and/or electrolytically induces appropriate reaction conditions to enhance reaction of the first and second reactants. Polarity reversals between the sample electrode (46) and remote electrodes (38), (42), (44) cause unreacted second reactant and/or by-products to migrate away from the immobilized first reactant. The techniques are useful for sequential chemical reactions such as sequencing or construction of proteins, polysaccharides and nucleic acids where cyclical additions and removals of reactants are required. The techniques are amenable to automated micro and nano scale construction and operation and allow direct electrophoretic (38) interfacing with chromatographic, HPCE and mass spectrophotometric equipment.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Geoffrey Stephen Begg, Richard John Simpson, Antony Wilks Burgess